Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Atropine and Bradycardia in Infants
NCT01819064Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2013
- Primary completion
- Jul 2013
- Countries
- 1
- Sponsor
- University at Buffalo
- Modality
- Classical Binding Small Molecules
- Drugs
- atropine
- Conditions
- bradycardia
01
Overview
Phase 4, open-label, single-arm trial of atropine in bradycardia, sponsored by University at Buffalo. Primary endpoint: Incidence of Bradycardia at 5 minutes. Started Feb 2013; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental
Infants <15kg receiving 0.005 mg/kg atropine
03
Who it enrols
Infants 0-2 years old, weighing <15kg (and <95th percentile), ASA I-II, undergoing elective surgery. Excludes history of heart disease, arrhythmia predisposition, use of heart rate influencing meds or routine anti-cholinergics, anticipated succinylcholine use, rapid sequence intubation, or known difficult airway.
04
Endpoints
Primary
Incidence of Bradycardia
Beyond the preview
Go deeper on NCT01819064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819064.